Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed/Refractory Follicular Lymphoma: later-stage trial registry
3 of 4 indexed Relapsed/Refractory Follicular Lymphoma trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Relapsed/Refractory Follicular Lymphoma: 4 US clinical trials tracked, 3 recruiting.
Relapsed/Refractory Follicular Lymphoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Epizyme, running 1 of these trials.
Enrollment posture brief
Registry condition relapsedrefractory-follicular-lymphoma
OPEN 3 | RECR 75% | LATE 4 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Relapsed/Refractory Follicular Lymphoma lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed/Refractory Follicular Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed/Refractory Follicular Lymphoma is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
BeiGene
NCT05100862
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme
NCT04224493
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Regeneron Pharmaceuticals
NCT06149286
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
NCT05371093
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed/Refractory Follicular Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed/Refractory Follicular Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed/Refractory Follicular Lymphoma page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Relapsed/Refractory Follicular Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Epizyme sponsors the most Relapsed/Refractory Follicular Lymphoma trials on record, review their full trial history before evaluating a specific study. See Epizyme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed/Refractory Follicular Lymphoma condition card totals 4 registered trials; most-linked intervention Lenalidomide; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.